Berger, Elizabeth1
1Wayne State University
Purpose: This presentation aims to provide a historical perspective on the development of thymosin beta 4 (Tβ4) and highlight the current advancements in our laboratory for the treatment of corneal infections.
Methods: A targeted literature review was carried out regarding the discovery and early research of Tβ4. Current experimental approaches in our lab include an in vivo mouse model of P. aeruginosa-induced corneal infection accompanied by in vitro studies to evaluate the efficacy of Tβ4 as an adjunctive therapy to antibiotics. A variety of molecular and cellular techniques (RT-PCR, flow cytometry, Western blot) are employed to investigate the underlying mechanisms. These are paired with behavioral assessments to establish therapeutic potential.
Results: Tβ4 was initially identified for its role in actin regulation and wound healing. Recent studies in our lab have demonstrated the therapeutic potential of Tβ4 as an adjunct to antibiotics, showing significantly improved disease response following infection. In vivo results further show a role for Tβ4 in corneal wound healing, regulating effector cell function, and activating pro-resolving pathways critical to the restoration of corneal structure and function.
Conclusions: The historical significance of Tβ4 as a multifunctional peptide has paved the way for its current application as an adjunctive treatment for corneal infection. Our ongoing research highlights its potential as a therapeutic agent, offering promising results in enhancing corneal healing and resolving infection. Future studies will focus on exploring its efficacy against other pathogens and advancing Tβ4 into clinical trials.
Last Updated: